SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Ps
The collaboration between SciSparc Ltd. and Clearmind Medicine Inc. has led to the publication of a patent application for a combination treatment using MEAI and PEA for treating cocaine addiction, based on preclinical trial results demonstrating significant reduction in cocaine-induced craving without impairing natural rewards. The study suggests that MEAI's effect on drug craving is specifically targeted at drug-related compulsions rather than the general reward system. This latest publication adds to multiple patent applications filed as part of their ongoing collaboration.
- The potential therapeutic benefits of this combination treatment could have significant implications for addressing cocaine addiction, a widespread and underserved health problem globally.
- What regulatory frameworks would be required to facilitate the commercialization of psychedelic-derived therapeutics like MEAI and PEA in the United States and other countries?